2025
Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma
Xiang X, Shetty K, Yu H, Mishra B, Wong L, Zhou X, Satapathy S, Crawford J, Latham P, Han S, Mathew B, Dagher N, Lau L, Cacaj F, Vegesna A, Dasarathy S, He A, Huang H, Amdur R, Mishra L. Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma. Liver International 2025, 45: e70325. PMID: 40919824, PMCID: PMC12416123, DOI: 10.1111/liv.70325.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorCarcinoma, HepatocellularCross-Sectional StudiesFemaleHumansLiver CirrhosisLiver NeoplasmsLogistic ModelsLongitudinal StudiesMaleMiddle AgedProspective StudiesProteomicsReceptor, Transforming Growth Factor-beta Type IIRisk AssessmentRisk FactorsTransforming Growth Factor betaConceptsRisk of hepatocellular carcinomaHepatocellular carcinomaCohort ALogistic regression analysisCohort CLongitudinal follow-up analysisTGF-bHepatocellular carcinoma riskCancer-related deathsProtein signaturesSix-protein panelSerum proteomic profilesLate-stage diagnosisAFP levelsCirrhotic patientsCohort BMulticenter studyLogistic regression analyses of cross-sectional dataClinical factorsMultivariable prediction modelEarly diagnosisMatched subgroupsPatientsCirrhosisFunction biomarkers
2023
Elucidating the role of blood metabolites on pancreatic cancer risk using two‐sample Mendelian randomization analysis
Zhong H, Liu S, Zhu J, Xu T, Yu H, Wu L. Elucidating the role of blood metabolites on pancreatic cancer risk using two‐sample Mendelian randomization analysis. International Journal Of Cancer 2023, 154: 852-862. PMID: 37860916, PMCID: PMC10843029, DOI: 10.1002/ijc.34771.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCarcinoma, Pancreatic DuctalGenome-Wide Association StudyHumansLongitudinal StudiesMendelian Randomization AnalysisPancreatic NeoplasmsConceptsPancreatic ductal adenocarcinomaPDAC riskBlood metabolitesGenetic instrumentsTwo-sample Mendelian randomization studyPancreatic Cancer Case-Control ConsortiumEPIC-Norfolk cohortPancreatic cancer riskEuropean ancestryPancreatic Cancer Cohort ConsortiumPotential side effectsCanadian Longitudinal StudyAssociations of metabolitesMendelian randomization studyTwo-sample Mendelian randomization (MR) analysisGenome-wide association studiesMendelian randomization analysisFatal malignancyDuctal adenocarcinomaCancer riskPDAC casesSide effectsAging CohortMetabolite biomarkersRandomization study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply